跳到主要內容

很遺憾,我們無法支援你的瀏覽器。如果可以,請升級到新版本,或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更新版本。如果無法升級,而且需要支援,請將你的回饋寄給我們。

我們衷心感謝你對這個新體驗的回饋。告訴我們你的想法打開新的分頁/視窗

Elsevier
與我們共同出版

Alyson Kelvin

AK

Alyson Kelvin

University of Saskatchewan, Canada

Alyson Kelvin, PhD. Dr. Kelvin打開新的分頁/視窗 is a Scientist II at the Vaccine and Infectious Disease Organization (VIDO)打開新的分頁/視窗, Saskatoon, Canada. She completed her HBSc at Western University (London, Canada, 2003) and her PhD at Queen’s University (Belfast, Northern Ireland, 2007). Dr. Kelvin’s expertise is in the fields of virology and vaccinology specifically focusing on the development of broadly protective vaccines for emerging viruses. She has researched several high-profile emerging viruses including the 2009 H1N1 pandemic influenza virus, avian H5N1 influenza virus, Mpox virus, SARS-CoV, and SARS-CoV-2. She is a member of expert panels for the control of emerging viruses including the Public Health Agency of Canada’s (PHAC) Avian Influenza Expert Panel. Dr. Kelvin has been recognized with a CEPI-CIHR Leadership Award in Vaccine Research as well as the Canadian Society for Virology Early Career Award of Excellence.